- Home
- TCI vs ZNTL Comparison
TCI vs ZNTL Comparison
Compare TCI & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TCI | ZNTL |
|---|---|---|
| Founded | 1983 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 308.7M | 289.0M |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | TCI | ZNTL |
|---|---|---|
| Price | $41.47 | $3.76 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $6.60 |
| AVG Volume (30 Days) | 1.5K | ★ 975.7K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 135.29 | 18.03 |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $49,060,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1,954.50 | ★ N/A |
| Revenue Growth | ★ 4.23 | N/A |
| 52 Week Low | $31.48 | $1.13 |
| 52 Week High | $59.65 | $6.95 |
Technical Indicators
Market Signals| Indicator | TCI | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 59.91 | 47.89 |
| Support Level | $34.57 | $3.75 |
| Resistance Level | $41.98 | $3.95 |
| Average True Range (ATR) | 1.29 | 0.25 |
| MACD | 0.27 | -0.04 |
| Stochastic Oscillator | 50.76 | 47.52 |
Price Performance
Historical ComparisonAbout TCI Transcontinental Realty Investors Inc.
Transcontinental Realty Investors Inc is a fully integrated externally managed real estate company. It operates in two business segments: the acquisition, development, ownership and management of multifamily properties; and the acquisition, development, ownership and management of commercial properties; which are office properties. The services for its commercial segment include rental of office space and other tenant services, including parking and storage space rental. The services for its multifamily segment include rental of apartments and other tenant services, including parking and storage space rental. the company derives maximum revenue from Multifamily Segment.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.